Satellos Bioscience Inc.
MSLE
$10.02
$0.849.15%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.96% | -33.75% | -25.46% | -3.80% | 8.68% |
| Total Depreciation and Amortization | 0.00% | -- | -100.00% | -- | -100.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.50% | 14.80% | -12.60% | 99.33% | -30.20% |
| Change in Net Operating Assets | 485.77% | 3.40% | -191.53% | 151.72% | 117.10% |
| Cash from Operations | 16.24% | -32.01% | -75.98% | 14.80% | 34.25% |
| Capital Expenditure | 100.00% | -- | 100.00% | 0.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 89.98% | -1,203.60% | 83.32% | -280.87% | -- |
| Cash from Investing | 89.98% | -1,203.75% | 83.32% | -280.97% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.92% | 32,043.54% | -79.00% | -49.71% | 69,500.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -- | -- | -- | -- |
| Cash from Financing | -99.93% | 35,206.80% | -79.00% | -49.71% | 69,500.00% |
| Foreign Exchange rate Adjustments | 131.40% | -150.29% | 210.32% | -132.02% | 16,033.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -227.11% | 193.61% | 49.77% | -443.56% | 174.79% |